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ABSTRACT
Objective: The purpose of this study was to assess
the effectiveness of a quality improvement (QI) plan
aimed at primary healthcare teams (PHCTs) to
optimise hypertension control and to compare it with
standard clinical care.
Methods:
Design Multicentric, non-randomised, quasi-
experimental controlled intervention study.
Setting 5 PHCTs in the intervention and 13 in the
standard care group in the province of Barcelona,
Catalonia, Spain.
Participants This is a population-based study in which
all patients over 18 years of age with a diagnosis of
hypertension before 1 January 2006 were included
(n¼9877 in the intervention group and n¼21704 in
the control group).
Intervention A QI plan that targeted primary care
professionals. The plan included training sessions,
implementation of recommended clinical practice
guidelines for the management of hypertensive
patients and audit and feedback to health
professionals.
Main outcome measure Prevalence of hypertensive
patients with an adequate blood pressure (BP) control.
Results: The adjusted difference between intervention
and standard care groups in the odds of BP control
was 1.3 (95% CI 1.1 to 1.6, p¼0.003). Results of the
mixed model on repeated measures showed that, on
average, an individual in the intervention group had an
increase of 92% in the odds of BP control (OR 1.9,
95% CI 1.7 to 2.1).
Conclusions: The implementation of a QI plan can
improve BP control. This strategy is potentially feasible
for up-scaling within the existing PHCTs.
Trial registration: ClinicalTrials.gov MS:
1998275938244441.
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ARTICLE SUMMARY
Article focus
- To assess the effectiveness of a QI programme
targeting health professionals to optimise BP
control in hypertensive patients. Other factors
associated with BP control were analysed.
Key messages
- The QI plan aimed at PHCTs (doctors, nurses and
administrative staff) implemented in our study
has proven effective to improve hypertension
control.
- A history of a cardiovascular event has a positive
effect in BP control.
- The addition of different antihypertensive drugs
to the management of hypertensive patients
without considering other aggravating factors
does not guarantee a better BP control.
Strengths and limitations of this study
- The population-based design and mixed-effects
modelling on repeated measures were the main
strengths of this study.
- The mixed models approach is a powerful
method for analysing data from longitudinal
studies, which include multiple measurements
on each participant.
- Most of the intervention effort in this study was
implemented with few additional resources.
- The duration of the study can be considered the
main limitation of this investigation. Longer term
studies that include unmeasured factors are
needed to determine the effectiveness and cost-
effectiveness of this measure and the impact of
a reduction in BP values on cardiovascular
morbimortality in the hypertensive population.
Valle `s-Ferna ´ndez R, Rodriguez-Blanco T, Mengual-Martı ´nez L, et al. BMJ Open 2012;2:e000507. doi:10.1136/bmjopen-2011-000507 1
Open Access ResearchBACKGROUND
High blood pressure (BP) ﬁgures among the most
common and important health problems in developed
countries. Hypertension is an established risk factor for
cardiovascular disease, stroke, kidney disease, all-cause
mortality and shortened life expectancy.
1 2
The prevalence of hypertension in Spain ranges from
20% to 47% in the population older than 20 years and
up to 65% in the population above 60 years of age.
3 It is
one of the main reasons for seeking medical attention in
primary care, particularly in the older population.
3
One in two cardiovascular deaths in Spanish individuals
over 50 is attributable to high BP.
4 A number of studies
carried out in Europe and in the USA have shown that BP
control in hypertensive patients is suboptimal.
35 e7
The Catalan Health Department Health Plan for
2007e2010 requires that the health systems implement
strategies to help at least 50% control of the hypertensive
population achieve good BP control.
8
Inadequate hypertension control has been associated
with various factors such as treatment compliance, dia-
betes, age, lifestyle, concomitant treatments, the tech-
nique and the equipment used to measure BP, etc.
3 679
Management by primary healthcare teams (PHCTs) is
one of the factors that can inﬂuence control of hyper-
tensive patients.
51 0 e12 Quality improvement (QI) strate-
gies can target health professionals, patients or both, and
many QI strategies have focused on improving hyperten-
sion control. These interventions can be classiﬁed as
provider education (materials and instructions given to
providers regarding appropriate care for patients),
provider reminders (prompts given to providers to
perform speciﬁc care tasks), provider audit and feedback,
patient education, patient reminders, promotion of self-
management, team management changes (creation of
multidisciplinary teams, addition of new team members,
change of roles, case or disease management), ﬁnancial
regulation and incentives or reimbursement changes.
12
Previous studies have shown the positive impact of
multifaceted QI interventions on BP control. However,
few of these studies have been analysed using the
appropriate methodology or have been designed as
population based. We believe therefore that the evalua-
tion of the effectiveness of a programme to improve
healthcare quality that targets primary healthcare
professionals with the aim to optimise BP control in the
whole hypertensive population is warranted.
5 10e12
We hypothesised that a plan for QI at the primary
healthcare level addressed to primary healthcare profes-
sionals would improve the management and control of
hypertensive patients. Our primary aim was to assess the
effectiveness of a QI programme targeting health profes-
sionals to optimise BP control in hypertensive patients.
Other factors associated with BP control were analysed.
METHODS
The study protocol received institutional review board
approval (IDIAP Jordi Gol Clinical Ethics Committee)
and conforms to the principles embodied in the Decla-
ration of Helsinki. The detailed methods and the study
protocol have been described elsewhere.
13
Recruitment and assignment
The study took place from January 2006 to April 2008.
All hypertensive patients diagnosed and registered in the
electronic medical records of 18 PHCTs (405232 inhabi-
tants) in the Barcelona province (Catalonia, Spain) were
included in this population-based study. All the Catalan
Institute of Health PHCTs invited to take part in this study
accepted.
Inclusion criteria: patients eligible to be enrolled in
the study were over 18 years of age and with a hyperten-
sion diagnosis before 1 January 2006. A diagnosis of
hypertension was considered when the doctor had
entered in the patient’s clinical record the relevant ICD-
10 code (I10), following the recommendations of the
European Hypertension Guidelines.
14 Exclusion criteria:
we excluded patients whose electronic medical records
contained no BP measurements in the year previous to
the study.
The non-random allocation to the control or inter-
vention group was decided on the basis of the PHCTs
administrative area. Each administrative area has its own
training and tasks strategies. The study design was there-
fore not randomised by PHCT to reduce the possibility of
contamination between the PHCTs of the same adminis-
trative area.
The intervention group consisted of ﬁve PHCTs in the
Cerdanyola-Ripollet area with a catchment population of
135505 at the onset of the study. The standard care group
(control group) consisted of 13 PHCTs in the Sabadell
area with a catchment population of 269727 inhabitants.
Both primary healthcare areas are comparable in terms of
population characteristics and socio-economic level. The
study was fully explained to health professionals in both
the standard care and intervention groups, and verbal
consent to participate was obtained.
Quality improvement intervention
The study intervention consisted in the implementation
of a QI plan targeted at all health professionals (approxi-
mately 430 physicians, nurses and administrative staff)
working in PHCTs in the Cerdanyola-Ripollet administra-
tive area. In the Sabadell administrative area, the number
of professionals was approximately 600. Brieﬂy, the QI plan
was divided in four phases:
1. Pre-intervention: non-validated BP monitors were
removed from the PHCTs examination rooms and
replaced by the digital OMRON M6 BP monitor.
15
The BP measurement technique was standardised in
both groups following the Clinical Practice Guide-
lines recommendations.
14 16 The software used to
store computerised clinical records was modiﬁed to
permit health professionals to enter speciﬁc data
related to hypertensive patients following the Catalan
Institute of Health guidelines on hypertension.
16
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was designed to train PHCTs’ doctors and nurses.
Posters and leaﬂets with speciﬁc educational contents
were made available to participants. A total of eight
workshops at each of the participating PHCTs took
place in three stages (mean attendance rate at
workshops was 65% with 6.59 mean assessment
points over a 10-points range):
– Year 2006: three sessions to introduce the QI plan
and review the criteria for diagnosis of hyperten-
sion, BP measurement method and criteria for
entering data in the computerised clinical record.
– Year 2006e2007: three sessions to discuss issues such
as the implementation of the QI plan, hypertension
treatment and approaches to poor compliance.
– Year 2008: two sessions to present the interim results
of the QI plan and the comprehensive management
of hypertensive patients.
3. Third phase (intervention group): from April 2007 to
April 2008 the interventions focused on the identiﬁ-
cation of patients with uncontrolled hypertension
and the improvement of their management. The
applied measures were: 6-month feedback to profes-
sionals; audits to evaluate the implementation of the
QI plan and a reference team (a doctor and a nurse)
assigned to each PHCT.
4. Fourth phase: evaluation of the effectiveness of a QI
plan.
Professionals allocated to the standard care group
followed the standard clinical management based on the
Catalan Institute of Health hypertension guidelines.
16
Masking
The study was not blinded at the PHCT or patient level
because of the nature of the intervention. The analyst
was unaware of the group allocation.
Data collection
Primary care professionals regularly enter the results and
activities of their work in the e-CAP (in English, electronic
Primary Care Centre) database. The data collection
procedure involved the reading of this computerised
clinical records database approximately every 4 months
from April 2007 to April 2008.
Outcomes and other variables
Control of hypertension based on the average systolic
blood pressure (SBP) and diastolic blood pressure
(DBP) readings recorded over the previous 12 months
was considered a dichotomous outcome variable (yes/
no). The median number of BP readings was three (IQR:
2e5). SBP and DBP were evaluated as dependent
continuous variables.
Control was deﬁned as SBP <140 mm Hg and DBP
<90 mm Hg. In patients with diabetes, heart failure or
renal failure, control values were deﬁned as SBP
<130 mm Hg and DBP <85 mm Hg. Other variables
considered were age (continuous); sex (male/female);
number of antihypertensive drugs as categorical (0/1/
2/3 or more); comorbidities as presence of diabetes
mellitus type I or II, heart failure or renal failure (yes/
no); cardiovascular events as presence of acute myocar-
dial infarction, angina or stroke (yes/no).
Analysis
Data were reported according to the standard published
by the TREND group.
17 Descriptive statistics were used
to describe the study population.
Differences between groups at baseline and at follow-
up times were assessed by comparing means, medians or
percentages, depending on the type of variable.
The analysis was performed at the individual level
using clustered data methods (grouping factor: PHCT)
18
and based on the intention-to-treat principle.
The following time points were considered for data
collection: baseline, 4, 9 and 12 months. Patients were
included in the analysis if data were available for at least
one follow-up time point in addition to the baseline
data. To address potential biases due to incomplete
follow-up data, we imputed missing values using the last
known value carried forward.
The intervention effect was assessed through observed
change and standardised effect size (SES).
19e21 For
between-group comparisons, SES were calculated
following the Kazis et al method.
20
For within-group comparisons, we used the longitu-
dinal form of SES, also known as the standardised
response mean (SRM).
19 20 22 Cohen’s rule of thumb for
interpreting the effect size index, which considers
a value of 0.2 as small, 0.5 as moderate and 0.8 or greater
as large, can be applied to the SRM.
19
Linear and logistic mixed-effects models with PHCTas
random effect were used to allow for within-PHCT
correlation to assess the effect of the intervention at
1-year follow-up, adjusted for baseline measurement and
for differences between groups in the individual vari-
ables. The OR for the logistic model was estimated as the
exponential function of the regression coefﬁcient, exp
(coefﬁcient).
The individual variables considered were age, sex,
number of antihypertensive drugs, comorbidity and
cardiovascular event.
We examined the effects of intervention over all
time points using mixed-effects models on repeated
measures.
23 24 Level 1 covariables varied by measurement
occasion and included time (age centred at 1-year follow-
up), number of antihypertensive drugs, comorbidity and
cardiovascular event. Level 2 covariables varied by subject
and included sex and group. Interactions between
covariables and the covariable ‘group’ were assessed.
All models were compared by the partial likelihood
ratio test and Akaike information criterion. All results
are shown with their 95% CIs. Statistical signiﬁcance was
set at p<0.01 (two tailed).
Stata SE V.11.0 (StataCorp LP) and SAS statistical
software V.9.1 (SAS Institute Inc.) were used for all
analyses.
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A total of 51642 people were included in the study;
16422 (5 PHCTs) were allocated to the intervention and
35220 (13 PHCTs) to the standard care group. The
exclusion rate was 33.5% (17315 patients). Follow-up
data were available for 92% of the patients. The ﬁnal
analysis included 31581 patients, 9877 (5 PHCTs) in the
intervention arm and 21704 (18 PHCTs) in the standard
care arm (ﬁgure 1).
The mean age of the standard care group was slightly
higher and presented a higher proportion of cardiovas-
cular events than the patients in the intervention group.
Otherwise the groups were clinically comparable (table 1).
A faster increase in the percentage of BP control was
observed in the intervention group during the follow-up
period. In the intervention group, BP was 1.3 times more
likely to be controlled than in the standard care group
(adjusted OR: 1.3, 95% CI 1.1 to 1.6, p¼0.003) (table 2).
The mean differences and SRM for within-group
comparisons of SBP and DBP were larger in the inter-
vention group than in the standard care group. A larger
mean difference and SRM were detected in SBP and DBP
at 1-year follow-up, with slightly higher values for DBP.
According to the Cohen guidelines,
19 only this change in
DBP can be considered a relevant change, and even so it
represents a small effect size (SRM¼0.21).
The larger signiﬁcant differences between interven-
tion and standard care group were found at 1-year
follow-up in favour of the intervention for SBP and DBP.
However, the SES did not reach even a small effect.
In the repeated measures analysis, the proportion of
patients who maintained BP control during follow-up was
38.4% (95% CI 38.1% to 38.7%) (intervention group:
40%, 95% CI 39.4% to 40.5%; standard care group:
37.7%, 95% CI 37.3% to 38.1%) and the proportion of
patients that improved over time (ie, achieved BP
control) was 6.6% (95% CI 6.4% to 6.7%) (intervention
group: 7.4%, 95% CI 7.1% to 7.7%; standard care group:
6.2%, 95% CI 6% to 6.4%). The difference between the
intervention and standard care groups in the percentage
of patients who maintained BP control was 2.3% (95% CI
1.6% to 3.0%) and the difference in those who improved
was 1.2% (95% CI 0.8% to 1.5%). The global trend
showed a highly signiﬁcant change in BP control over time
(p<0.001).
In phases 2, 3 and 4, the percentage of patients who
were not taking antihypertensive drugs (BP drugs) at
baseline and remained free of BP drugs was 79.5%,
72.9% and 66.4% in the intervention group and
66.0%, 58.1% and 54.1% in the standard care group,
respectively.
In the multilevel analysis, we found that after 1 year of
follow-up, an individual in the intervention group was
expected on average to have an increase of 92% (OR:
exp (0.65)¼1.9, 95% CI 1.7 to 2.1) in the odds of BP
control, a reduction of 1.77 mm Hg on the SBP (95% CI
 2.10 to  1.45) and of 0.78 mm Hg in DBP (95% CI
 0.98 to  0.57). The effect of time showed that a patient
in the intervention group experienced an increase in BP
control together with a reduction in SBP and DBP over
time (table 3).
At 1 year of follow-up, another associated factor that
increased the probability of BP control was the presence
of a cardiovascular event, also signiﬁcantly associated
with a reduction in SBP and DBP. Furthermore, the
presence of comorbidity was associated with lower DBP
but with a worse BP control and higher SBP. The use of
two or more antihypertensive drugs was associated with
Figure 1 Flow chart of study.
BP, blood pressure; PHCT,
primary healthcare teams.
18 PHCT
405 232 inhabitants
Intervention group
(5 PHCT= 
16 422 hypertensive patients)
Standard care group
(13 PHCT= 
35 220 hypertensive patients)
Excluded (n=5756)
Did not meet inclusion criteria (n=3114)
No BP electronic  clinical  record 
measurements in the last year (n=2642)
Excluded (n=11 559)
Did not meet inclusion criteria (n=4369)
No BP electronic clinical record 
measurements in the last year (n=7190)
Standard care group 
(Administrative area Sabadell: 13 
PHCT=269 727 inhabitants)
Intervention group
(Administrative area Cerdanyola-Ripollet: 5 
PHCT=135 505 inhabitants)
Target allocated
(5 PCHT; n =10 666)
Target allocated
(13PCHT; n=23 661)
Lost to follow-up
Patients without follow-up BP 
measurements (n=789)
Migrated (n=0)
Lost to follow-up
Patients without follow-up BP  
measurements (n=1895)
Migrated (n= 62)
Patients analysed
(n=9877)
Patients analysed
( n=21 704)
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but lower DBP compared with patients using one
antihypertensive drug. In all three models, there was
strong evidence of variation in the outcomes between
participants, as indicated by the random intercepts
(table 3).
DISCUSSION
Principal ﬁndings of the study
Our results show a signiﬁcant improvement in the
intervention compared with the standard care group,
consistent across all assessed outcomes. The different
models used to analyse the data from our study indicate
that the implementation of a QI plan is effective in
increasing BP control and decreasing both SBP and DBP.
The analysis adjusted by baseline data shows that
patients in the intervention group had 30% more
probability of an adequate BP control after 1-year follow-
up. In the intervention group, mean SBP and DBP values
decreased 2.1 mm Hg and 0.9 mm Hg, respectively,
compared with the patients from the standard care
group.
The patients in the intervention group had a higher
probability of an adequate BP control (OR 1.9), as shown
by the repeated measures analysis. The percentage of
patients that maintained a good BP control or that
changed from poor to adequate BP control was larger in
the intervention (2.3%) than in the standard care group
(1.2%).
Comparison with other studies
Various reviews and meta-analyses on the effectiveness of
QI strategies to improve BP control have been
published.
5 10e12 In general, QI interventions on BP
control are considered effective, although the results are
variable and difﬁcult to compare. For instance, the
change in SBP and DBP values in QI interventions that
included monitoring and feedback for providers was
1.5/0.6 mm Hg,
12 a result similar to the current study.
There is also a recent study that evaluated the effective-
ness of a continuing medical education programme to
train primary care providers in evidence-based guide-
lines for hypertension prevention and control.
25 The
change in BP was 1.99 mm Hg in SBP and 1.49 mm Hg
in DBP. This intervention was a cost-effective strategy to
address hypertension.
26 The study reported by Landon
and colleagues
27 was carried out in asthmatic and dia-
betic patients. Despite the lack of differences between
groups, in the hypertension subgroup, the percentage of
adequate control was similar to ours.
Table 1 Patient characteristics
Total Standard care group Intervention group p Value*
No. of PHCTs 18 13 5
No. of patients 31581 21704 9877
Demographic/clinical variables
Age, years (mean (SD)) 68.6 (11.6) 69.1 (11.5) 67.6 (11.6) <0.001
Sex, female 18825 (59.6) 12914 (59.5) 5911 (58.8) 0.562
No. of BP drugs (mean
(SD); median (IQR))
1.4 (0.8); 1 (1e2) 1.4 (0.9); 1 (1e2) 1.5 (0.9); 1 (1e2) 0.028y
Patients with antihypertensive drugs, n (%)
0 3315 (10.5) 2319 (10.7) 996 (10.1) 0.031
1 15209 (48.1) 10501 (48.4) 4708 (47.7)
2 9068 (28.7) 6212 (28.6) 2856 (28.9)
3 or more 3989 (12.6) 2672 (12.3) 1317 (13.3)
Comorbidityz 9490 (30.0) 6584 (30.3) 2906 (29.4) 0.101
Diabetes mellitus 8309 (26.3) 5720 (26.3) 2589 (26.2) 0.79
Renal failure 1022 (3.2) 721 (3.3) 301 (3.1) 0.201
Heart failure 862 (2.7) 648 (2.9) 214 (2.2) <0.001
CV eventx 3839 (12.2) 2928 (13.5) 911 (9.2) <0.001
Outcome characteristics{
BP control 14195 (44.9) 9854 (45.4) 4341 (43.9) 0.016
SBP, mm Hg (mean (SD)) 138.3 (13.6) 138.1 (13.6) 138.7 (13.7) <0.001
DBP, mm Hg (mean (SD)) 79.5 (8.5) 79.4 (8.3) 79.5 (8.9) 0.231
Note. The diseases considered in the CV risk calculation tables in the ICS clinical practice guideline used in this study, as well as other
international guidelines,
14 16 are heart failure, kidney failure and diabetes mellitus. Hypertension was deﬁned as SBP $140 mm Hg and DBP
$90 mm Hg of clinical BP measurements. In patients with diabetes, heart failure or renal failure (code ICD-10: E10eE11eN17eN18e
N19eI50), hypertension was deﬁned as SBP $130 mm Hg and DBP $85 mm Hg. BP control was deﬁned as SBP <140 mm Hg and DBP
<90 mm Hg. In patients with diabetes, heart or renal failure, control values were deﬁned as SBP <130 mm Hg and DBP <85 mm Hg.
*p Values were calculated from a Student t test, the c
2 test or medians’ test as appropriate, by comparing the different intervention groups.
yp Value for median comparison.
zComorbidity: presence of diabetes mellitus type I or II, heart failure or renal failure.
xCV: patient’s clinical history of ICD-10 codes of acute myocardial infarction, angina or stroke.
{BP was calculated from the mean of 3.5 (SD: 2.2) (median (IQR: 3 (2e5))) BP readings obtained during 1 year.
BP, blood pressure; CV, cardiovascular; DBP, diastolic blood pressure; SBP, systolic blood pressure; PHCTs, primary healthcare teams.
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Intervention for control of hypertension (INCOTECA Project)Effectiveness varies according to the study. BP control
and reduction in SBP and DBP values are analysed in two
studies in relation to the type of intervention carried out:
an educational intervention aimed at patients and general
practitioners,
28 and a qualitative intervention aimed at
general practitioners,
29 very similar to our study. The
results related to the general practitioners differed from
the results of our investigation. In the ﬁrst study cited,
effectiveness was evaluated after 2 years and no improve-
ment in BP control was observed. However, they obtained
a more signiﬁcant reduction in SBP and DBP values (5
and 4 mm Hg, respectively). This could be explained by
their very low levels of BP control (27.8%) at the onset of
the study, their very high SBP and DBP means
(153.3 mm Hg and 92.9 mm Hg, respectively) and the
health infrastructure of a developing country (Pakistan).
Therefore, even if SBP and DBP values improved signiﬁ-
cantly, BP control was below the target of the BP Control
Clinical Practice Guidelines.
28
In the second study cited, SBP reduction after
6 months was 0.3 mm Hg (95% CI  1.5 to 2.2,
p¼0.76).
29 The following reasons may account for this
lack of effect: (1) the intervention was addressed only to
physicians; (2) the analysis was based on the patients that
had completed follow-up and (3) the study population
represented a relatively healthy cohort with high rates of
BP control at baseline.
On the other hand, in a study similar to ours with the
aim to reduce cardiovascular risk in hypertensive patients,
Gomez Marcos and colleagues
30 showed that the differ-
ences between the intervention and control groups in SBP
and DBP values were larger,  9.0 mm Hg (95% CI  11.3
to  6.7) and  3.9 mm Hg (95% CI  5.4 to  2.4),
respectively. The greater reduction of BP values in this
Table 3 Effects of covariables on BP control, SBP and DBP (N¼31581)
BP control* SBPy DBPy
Adjusted b SE p Value Adjusted b SE p Value Adjusted b SE p Value
Fixed effects
Final status
Intercept 0.54 0.05 <0.0001 137.93 0.14 <0.0001 80.01 0.09 <0.0001
Group (ref. control) 0.65 0.06 <0.0001  1.77 0.17 <0.0001  0.78 0.10 <0.0001
Gender (ref. male) 0.14 0.05 0.006  0.11 0.14 0.434  0.60 0.09 <0.0001
Number of antihypertensive drugs (ref. 1 drug)
0 drugs 0.16 0.08 0.049  0.53 0.18 0.004 0.01 0.11 0.898
2 drugs  0.44 0.05 <0.0001 0.89 0.12 <0.0001  0.31 0.08 <0.0001
$3 drugs  0.69 0.07 <0.0001 1.49 0.17 <0.0001  0.79 0.10 <0.0001
Comorbidity (ref. no)  3.92 0.06 <0.0001 1.49 0.13 <0.0001  1.42 0.08 <0.0001
Cardiovascular event (ref.
no)
0.51 0.06 <0.0001  1.05 0.16 <0.0001  2.01 0.10 <0.0001
Rate of change
Time  0.21 0.04 <0.0001 0.93 0.11 <0.0001  0.29 0.07 <0.0001
Time 3 group 0.80 0.06 <0.0001  2.51 0.15 <0.0001  0.78 0.09 <0.0001
Time 3 number of antihypertensive drugs (ref. 1 drug)
0 drugs  0.12 0.10 0.217 0.30 0.24 0.206 0.31 0.14 0.028
2 drugs 0.26 0.06 <0.0001  0.92 0.16 <0.0001  0.52 0.09 <0.0001
$3 drugs 0.34 0.09 <0.0001  2.09 0.21 <0.0001  1.04 0.12 <0.0001
BP control* SBPy DBPy
Variance SE p Value Variance SE p Value Variance SE p Value
Random effects
Level 1
Within-person (residual) 26.65 0.15 <0.0001 9.65 0.05 <0.0001
Level 2
In ﬁnal status (intercept) 12.64 0.24 <0.0001 165.83 1.48 <0.0001 67.20 0.59 <0.0001
In rate of change (time) 104.35 1.26 <0.0001 36.14 0.44 <0.0001
Covariance 53.74 1.06 <0.0001 20.30 0.40 <0.0001
Goodness of ﬁt
Deviance 115503 906066.8 780098.3
AIC 115531 906100.8 780132.3
BIC 115648 906243.0 780274.4
Mixed-effects models of repeated measures (phases 1e4). Time was patient’s age centred at 1-year follow-up (ﬁnal status).
*SAS Proc Nlmixed.
ySAS Proc mixed, full ML.
AIC, Akaike’s Information Criterion; BIC, Bayesian Information Criterion; BP, blood pressure; DBP, diastolic blood pressure; ref., Reference;
SBP, systolic blood pressure.
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Intervention for control of hypertension (INCOTECA Project)study compared with our analysis of an entire hypertensive
population could be explained by their recruitment of
only 849 hypertensive patients with a long-term regular
follow-up in the PHCTs. Although such studies allow
health professionals to focus on the follow-up of these
patients to achieve better results, the lower patient
numbers limit their external validity. The impact of
a previous cardiovascular event on BP control in these
studies is not known.
27e30
Despite the small impact of our intervention on SBP
and DBP, we consider these results clinically relevant
because several studies have shown that small reductions
in SBP and DBP in the general population are associated
with a decrease in the number of cardiovascular events:
a 10% reduction in stroke mortality and around 7%
reduction in mortality due to cardiovascular disease in
the middle-aged population have been associated to
a 2 mm Hg decrease in SBP.
31 32
It is important to emphasise that other factors inﬂu-
encing poor BP control are the presence of comorbid-
ities and treatment with two or more antihypertensive
drugs. Following the recommendations in the clinical
guidelines, it is sometimes necessary to increase the
number of drugs to improve BP control.
14 16 33 34
However, this was not a ﬁnding of our study, a difference
that might be explained by unknown or unmeasured
confounding factors that we did not analyse, such as the
patient’s treatment compliance.
Strengths and weaknesses of the study
The population-based design and mixed-effects model-
ling on repeated measures were the main strengths of
this study. The extensive catchment population included
in the investigation reinforces the external validity of our
ﬁndings. Most studies on similar QI strategies have been
carried out in samples of hypertensive patients.
27e29 35
The mixed models approach is a powerful method for
analysing data from longitudinal studies, which include
multiple measurements on each participant.
24 36
This approach allows the use of all available data and
explicit modelling of the within- and between-person vari-
ation in the outcome while taking into account the corre-
lation between measurements obtained from the same
individual, which other classical models of analysis cannot
explore.
We would like to emphasise that most of the inter-
vention in this study was implemented with few addi-
tional resources since the QI plan was carried out with
the usual human and ﬁnancial resources allocated to the
health area of the intervention group. Only the publi-
cation of the training material in the form of posters and
leaﬂets and the replacement of sphygmomanometers
with digital equipment involved additional costs. Some-
times the main difﬁculty of improving care lies in the
feasibility of including in the PHCT routine and at low
cost simultaneous strategies that have an impact on every
hypertensive patient.
The duration of the study can be considered the main
limitation of this investigation. We have not been able to
determine if the improvements are sustainable after the
intervention was ﬁnalised, though a study carried out in
Spain suggested that the effects of quality interventions
on hypertension tend to decrease over time.
30 Also, we
do not know if a better hypertension control in the
intervention group is related to a decrease in cardio-
vascular morbimortality.
The impossibility of randomising by PHCT is another
limitation of the study, partially compensated by
selecting two different administrative health areas as
the control and intervention groups to prevent
contamination issues among PHCT professionals of the
same area.
The BP measurements used in the study were obtained
as part of routine care and were therefore subjected to
error and variability between professionals, as reﬂected
in the electronic medical record (EMR). To minimise
variability, training workshops on BP measurement
methods and proper data entry in the clinical records
took place throughout the 1-year project period.
Policy implications, future research and conclusions
The results of this study show that in our setting, it is
feasible to implement a QI plan for the improvement of
hypertension control in the PHCTs. The design of this
QI plan that will permit its integration in the regular
clinical care of the PHCT professionals (doctors, nurses
and administrative staff) without a signiﬁcant increase in
workload or cost is its main (and important) advantage.
Longer-term studies that include unmeasured factors are
needed to determine the effectiveness and cost-effec-
tiveness of this intervention and the impact of a reduc-
tion in BP values on cardiovascular morbimortality in the
hypertensive population.
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